Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly's Basaglar Insulin Glargine Will Be US Blockbuster

Executive Summary

With second-quarter sales of over $232m in the US, Eli Lilly's Basaglar hybrid insulin glargine is close to becoming a $1bn blockbuster on a proforma annual basis. Global sales of the brand are already tracking well ahead of $1bn.

You may also be interested in...



Should US Insulins Be Treated As Biologics?

Against a backdrop of continued outcry over insulin costs in the US and the looming FDA-imposed transition of insulins to biologic status in early 2020, legislators and manufacturers alike are still lobbying for alternative approaches to the essential diabetes treatment.

Mylan Rolls Out Semglee Insulin In Australia

Immediately upon reimbursement listing, Mylan has launched in Australia the insulin glargine biosimilar that it co-developed with India’s Biocon. 

Novo Nordisk Follows Lilly To Lower-Priced Insulin

Novo Nordisk will launch US authorized generics of its NovoLog and NovoLog Mix at half the price of the brands from the start of 2020.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel